tebnow← All categories
Category

Pharma & Medications

593 articles indexed

Pfizer's Talzenna and Xtandi Combo Achieves Phase 3 Success in Castration-Sensitive Prostate Cancer

Pfizer has announced a significant victory for its combination therapy of Talzenna (talazoparib) and Xtandi (enzalutamide) in a Phase 3 clinical trial targeting metastatic castration-sensitive prostate cancer. This achievement follows the recent expansion of the FDA label for the same combination in metastatic castration-resistant prostate cancer, indicating a strategic advantage over Johnson & Johnson's PARP inhibitor Akeega (olaparib and abiraterone). The results suggest that Pfizer's therapy may be applicable to a broader patient population, potentially enhancing treatment options for those diagnosed with this aggressive form of prostate cancer. The implications of this trial are substantial, as castration-sensitive prostate cancer represents a significant segment of the prostate cancer patient population. With the successful Phase 3 results, Pfizer is poised to capture a larger market share and provide new hope for patients who have limited treatment options. The combination therapy's efficacy could lead to improved survival rates and quality of life for these patients. As the landscape of prostate cancer treatment evolves, healthcare professionals will need to stay informed about the latest developments in combination therapies. The upcoming regulatory decisions and potential market entry of this combination could reshape treatment protocols and patient management strategies in oncology. Pfizer's advancements may also prompt further research into combination therapies for other cancer types, highlighting the ongoing innovation in cancer treatment.

Fierce Pharma

oncology / prostate cancer / clinical trials / FDA / combination therapy

Incyte Targets First-Line DLBCL Market with Monjuvi Combination Therapy

Incyte is strategically positioning its drug Monjuvi in the competitive first-line treatment landscape for diffuse large B-cell lymphoma (DLBCL). The company is optimistic about Monjuvi's positive results from phase 3 trials, which demonstrated efficacy across various patient subgroups. This positions Monjuvi as a potential alternative to the standard R-CHOP regimen and Roche's Polivy, particularly as the market anticipates the arrival of newer therapies like T-cell engagers. The implications of these developments are significant, as they could reshape treatment protocols and improve outcomes for patients with DLBCL. As the landscape evolves, healthcare professionals will need to stay informed about the comparative effectiveness of these therapies and their potential impact on patient care.

Fierce Pharma

Philips Enhances Pediatric MRI Experience with Disney Animation Integration

Philips has introduced a new feature in its MRI machines aimed at reducing anxiety in pediatric patients by incorporating animated Disney characters and stories into the imaging process. This innovative approach seeks to create a more comforting and engaging environment for children undergoing MRI scans, which can often be intimidating and stressful. By leveraging familiar and beloved characters, Philips aims to distract young patients and ease their fears during the procedure. The integration of Disney animations is significant as it addresses a common challenge in pediatric healthcare: the difficulty children face when undergoing medical imaging. Anxiety can lead to movement during scans, potentially compromising the quality of the images and necessitating repeat procedures. By making the experience more enjoyable, Philips hopes to improve patient cooperation and overall satisfaction. This initiative is particularly relevant in the context of rising awareness about the importance of mental and emotional well-being in healthcare settings. As hospitals and clinics strive to create child-friendly environments, Philips' collaboration with Disney represents a creative solution that could set a new standard in pediatric imaging. Moving forward, Philips plans to evaluate the effectiveness of this integration through feedback from healthcare providers and families. The company is also exploring further partnerships to enhance the pediatric healthcare experience, potentially expanding this concept to other medical procedures beyond MRI scans.

Fierce Pharma

Pharmaceutical Industry Urged to Enhance Support for Young Adult Cancer Patients Amid Rising Rates

A recent report by Omnicom Health highlights the urgent need for pharmaceutical companies to modernize their patient support programs in response to increasing cancer rates among adults aged 18 to 49. This demographic has seen a notable rise in cancer diagnoses, prompting calls for more tailored support services that address the unique challenges faced by younger patients. The report emphasizes that effective patient support is crucial not only for improving treatment adherence but also for enhancing overall patient outcomes. As the incidence of cancer in this age group continues to grow, stakeholders in the healthcare sector are urged to collaborate and innovate in developing resources that meet the specific needs of young adult cancer patients. The findings underscore the importance of adapting existing frameworks to ensure that younger patients receive the comprehensive care and support they require during their treatment journey.

Fierce Pharma

MannKind Gains Pediatric Approval for Afrezza, Aiming for Market Impact

MannKind Corporation has received pediatric approval for its inhaled insulin product, Afrezza, marking a significant milestone after over a decade of challenges in the market. This approval is expected to enhance the company's sales prospects and provide a much-needed boost to its performance. The inhaled insulin, which is designed for children with diabetes, offers a novel delivery method that could improve adherence and patient experience compared to traditional insulin injections. The approval comes at a crucial time as the demand for innovative diabetes management solutions continues to grow. With approximately 1.6 million children in the United States diagnosed with diabetes, the potential market for Afrezza is substantial. This development not only highlights the importance of advancing treatment options for younger patients but also positions MannKind to compete more effectively against established insulin therapies. Moving forward, MannKind plans to implement targeted marketing strategies to raise awareness among healthcare providers and families about the benefits of Afrezza. The company is optimistic that this approval will lead to increased prescriptions and ultimately improve the quality of life for pediatric patients managing diabetes. As the market evolves, the success of Afrezza will depend on its acceptance by both healthcare professionals and patients alike.

Fierce Pharma

Merck Highlights Promising Cancer Drug Sacituzumab Tirumotecan at ASCO Conference

At the recent American Society of Clinical Oncology (ASCO) conference, Merck & Co. emphasized the potential of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate licensed from China-based Kelun-Biotech, as a key player in its oncology portfolio. This comes as Merck prepares for the impending patent expiration of its blockbuster cancer drug, Keytruda. The company has initiated an extensive Phase 3 clinical program for sac-TMT, which includes 17 studies across various tumor types, reflecting its confidence in the drug's efficacy. Recent data presented at ASCO revealed that a combination of sac-TMT and Keytruda significantly reduced the risk of disease progression or death by 65% compared to Keytruda alone in a Phase 3 trial focused on lung cancer in China. Although the median progression-free survival has not yet been reached for sac-TMT recipients, the results indicate a promising trend in survival outcomes. Analysts noted that the safety profile of sac-TMT appears favorable, contributing to a 5% increase in Merck's stock value following the announcement. Despite the encouraging results, uncertainties remain regarding sac-TMT's performance in global trials, particularly since the study did not utilize a Keytruda-chemotherapy combination as a control. Comparisons with other TROP2-targeting drugs, such as AstraZeneca's Datroway and Gilead's Trodelvy, will be critical in determining sac-TMT's market position. Merck's leadership remains optimistic, citing unique technical attributes of sac-TMT that may enhance its therapeutic outcomes. As the company continues to explore the drug's potential in various cancers, including a successful trial in endometrial cancer, the future of sac-TMT appears promising, although it faces competition from emerging treatment standards in oncology.

BioPharma Dive · 2d ago

Bristol Myers Squibb Reports Promising Phase 3 Results for Mezigdomide in Multiple Myeloma

Bristol Myers Squibb has announced significant findings from its Phase 3 trial of mezigdomide, an experimental drug for multiple myeloma, presented at the American Society of Clinical Oncology meeting. The study, known as SUCCESSOR-2, demonstrated that patients receiving mezigdomide in combination with Amgen's Kyprolis and a steroid experienced a delay in disease progression or death by approximately 10 months compared to those receiving only the standard therapies. Specifically, the mezigdomide regimen resulted in an 18-month progression-free survival, compared to just 8.3 months for the control group, highlighting its potential as a new treatment option for patients with relapsed or refractory multiple myeloma. The trial included patients who had previously undergone at least one treatment line, with many having received two or more therapies. The results showed that 80% of patients on the mezigdomide regimen responded positively to treatment, while only 53% of those in the control group did. Furthermore, 27% of patients receiving mezigdomide had no detectable disease, compared to 9% in the comparator group. However, the combination therapy was associated with a higher incidence of severe adverse events, including low white blood cell counts and infections. These findings are particularly relevant as the treatment landscape for multiple myeloma becomes increasingly competitive, with the introduction of cell therapies and bispecific antibodies. Mezigdomide is part of a new class of drugs known as CELMoDs, which Bristol Myers is positioning as successors to its established therapies, Revlimid and Pomalyst. The company is also conducting further studies, including SUCCESSOR-1, to evaluate mezigdomide in combination with other treatments. As the need for effective therapies grows, especially for patients facing drug resistance, the results from the SUCCESSOR-2 trial could significantly impact future treatment protocols in multiple myeloma care.

BioPharma Dive · 2d ago

Leadership Change at Allogene; Agios Drug Fails Mid-Stage Trial

David Chang, CEO of Allogene Therapeutics, will step down after eight years, with Zachary Roberts set to take over on July 1. Chang co-founded the company and has been instrumental in its development of donor-derived cell therapies for lymphoma. His departure marks a significant transition for Allogene, which has faced various challenges in its journey to bring innovative therapies to market. Despite this leadership change, Chang will remain on the board, ensuring continuity in strategic oversight. In a separate development, Agios Pharmaceuticals announced that its experimental drug, tebapivat, has failed a mid-stage trial for lower-risk myelodysplastic syndromes (MDS). This setback is notable as tebapivat was positioned as a next-generation alternative to Pyrukynd, Agios's existing treatment. The company has decided not to pursue further development of tebapivat for this indication, although a Phase 2 study in sickle cell disease is still ongoing, with results anticipated later this year. Additionally, AbbVie has received FDA approval for Decnupaz, a therapy acquired through a $10 billion buyout of ImmunoGen. This drug is now approved for treating blastic plasmacytoid dendritic cell neoplasma, a rare and aggressive blood cancer, with clinical trials showing that approximately 70% of patients had no detectable cancer post-treatment. Furthermore, AstraZeneca's immunotherapy Imfinzi has been approved for use in combination with Bacillus Calmette-Guérin for non-muscle invasive bladder cancer, demonstrating a 32% reduction in relapse risk. Lastly, the FDA is reviewing BridgeBio Pharma's BBP-418, aimed at treating a specific form of limb-girdle muscular dystrophy, with a decision expected by November 27. This marks a promising advancement in rare disease therapies, following a series of successful clinical trials by BridgeBio.

BioPharma Dive · 2d ago

Pfizer Partners with Innovent in $10 Billion Cancer Drug Collaboration

Pfizer has entered into a significant partnership with Innovent Biologics, potentially worth over $10 billion, to develop up to 12 cancer drugs. This collaboration includes eight early-stage candidates from Innovent and four discovery programs proposed by Pfizer, focusing on innovative therapies such as antibody-drug conjugates and multispecific antibodies. Innovent will lead the discovery and early research phases, while Pfizer will assume global development responsibilities following Phase 1 trials. The deal is structured to provide Innovent with an upfront payment of $650 million, with the potential for an additional $9.85 billion based on milestone achievements. Furthermore, Innovent will receive royalties from any approved drugs resulting from this collaboration. This partnership exemplifies the increasing trend of U.S. and European pharmaceutical companies collaborating with Chinese biotech firms, driven by China's rapid advancements in drug development. In recent years, the number of licensing agreements between Western and Chinese companies has surged, raising concerns in the biotech community and among U.S. policymakers about the implications for American pharmaceutical leadership. Since July 2022, several major pharmaceutical companies, including GSK, Takeda, and AstraZeneca, have engaged in similar multi-drug partnerships, indicating a shift in the global pharmaceutical landscape. Pfizer's chief oncology officer, Jeff Legos, emphasized the potential of this alliance to enhance their oncology pipeline and accelerate the delivery of innovative treatments that could significantly impact patient care. The Innovent deal represents Pfizer's largest investment in China-discovered medicines to date, reflecting its strategic focus on expanding its oncology portfolio for future growth.

BioPharma Dive · 2d ago

CVS Caremark Reinstates Coverage for Eli Lilly's Obesity Drug Zepbound and Introduces Foundayo

CVS Caremark, the leading pharmacy benefit manager in the United States, has announced the restoration of coverage for Eli Lilly's obesity medication, Zepbound. This decision is expected to significantly enhance access for patients who rely on insurance to afford their obesity treatments. The reinstatement of coverage comes at a crucial time as obesity rates continue to rise, impacting millions of Americans and contributing to various health complications. Additionally, CVS has introduced a new obesity treatment pill, Foundayo, further expanding the options available to patients. This move not only reflects CVS's commitment to addressing the obesity epidemic but also highlights the growing importance of accessible medication in managing chronic conditions. As CVS implements these changes, healthcare providers and patients alike will need to stay informed about the coverage details and potential impacts on treatment plans.

Fierce Pharma

Global Pharma Leaders Urge Japan to Enhance Biopharma R&D Investment

In a significant meeting, more than 20 leaders from the global pharmaceutical industry convened with Japan's Prime Minister Sanae Takaichi to discuss the country's diminishing share in biopharmaceutical research and development (R&D). This gathering highlights the urgent need for Japan to bolster its position in the competitive biopharma landscape, which is crucial for innovation and economic growth. The decline in Japan's R&D share poses risks not only to the pharmaceutical sector but also to the broader healthcare ecosystem, potentially impacting drug availability and patient care. The discussions aimed to identify strategies and policies that could reinvigorate investment in biopharma R&D, ensuring that Japan remains a key player in the global market. Moving forward, stakeholders will be closely monitoring the government's response and any proposed initiatives that may arise from this high-level dialogue.

Fierce Pharma

AstraZeneca's Imfinzi Approved for High-Risk Non-Muscle-Invasive Bladder Cancer Treatment

AstraZeneca has received FDA approval for Imfinzi, a PD-L1 inhibitor, marking a significant advancement in the treatment of high-risk non-muscle-invasive bladder cancer. This approval allows Imfinzi to be used in combination with standard care, positioning it as the first immunotherapy regimen for this patient population. The approval is particularly noteworthy as it intensifies competition with Merck's Keytruda, which has been a dominant player in the immunotherapy space. The introduction of Imfinzi is expected to provide new options for patients who are often at a higher risk of disease progression. As the landscape of bladder cancer treatment evolves, healthcare professionals will need to consider the implications of this new therapy on treatment protocols and patient outcomes.

Fierce Pharma

CVS Expands Coverage for Eli Lilly's Obesity Drugs, Leveling Competition with Novo Nordisk

CVS Caremark has announced a significant shift in its drug coverage policies, placing Eli Lilly's new oral weight loss medication, Foundayo, on its formularies starting June 1, 2026. This decision also reinstates coverage for Lilly's injectable drug, Zepbound, as a preferred option beginning October 1, 2026. Previously, Novo Nordisk's Wegovy had enjoyed preferred status, giving it a competitive edge in the GLP-1 obesity treatment market. With this change, both Foundayo and Zepbound will now be covered by all three of the largest pharmacy benefit managers (PBMs) in the United States, potentially increasing access for millions of patients. The implications of CVS's decision are significant for Eli Lilly, as it reverses a previous setback when CVS had favored Novo's Wegovy, causing Lilly's stock to drop. Following the announcement, Lilly's shares rose nearly 6%, indicating investor optimism about the expanded market access for its drugs. Analysts suggest that this move will meaningfully increase the prescription pool for both Foundayo and Zepbound, which is crucial for Lilly as it seeks to enhance its market presence in the competitive obesity treatment landscape. Both Eli Lilly and Novo Nordisk are actively pursuing strategies to broaden their customer bases, including offering lower-cost options and collaborating with telehealth services. Additionally, both companies are adjusting their pricing strategies for Medicare patients, further expanding their reach. While Lilly has gained a larger share of the injectable market, Foundayo's adoption has lagged behind Wegovy, with only 30% of the prescription trajectory achieved by Wegovy within the same timeframe. Novo Nordisk maintains that Wegovy will continue to have strong formulary access, ensuring that patients currently using the drug will not experience any disruptions in their treatment.

BioPharma Dive · 3d ago

US Healthcare and Life Sciences Navigate Challenges Amid Opportunities, AlixPartners Survey Reveals

A recent survey conducted by AlixPartners highlights the increasing pressures faced by healthcare and life sciences firms in the United States due to evolving regulatory, pricing, and policy dynamics. The survey indicates that these challenges are intensifying quarterly, prompting companies to adapt their strategies to maintain profitability. This situation is critical as it not only affects the financial health of these firms but also has broader implications for patient care and access to medical innovations. The survey underscores a 'vast field of opportunity' that exists despite these pressures, suggesting that firms that can navigate the complexities of the current landscape may find new avenues for growth. Key stakeholders, including healthcare providers, pharmaceutical companies, and policy makers, must remain vigilant and responsive to these changes to ensure sustainable operations. As the healthcare sector continues to evolve, understanding the interplay between policy changes and market dynamics will be essential for stakeholders. The findings from this survey may serve as a catalyst for discussions on how to balance profitability with the need for accessible and affordable healthcare solutions. Moving forward, companies will need to leverage innovative strategies to thrive in this challenging environment.

Fierce Pharma

Ivonescimab's Harmoni-6 Results to be Scrutinized at ASCO 2026 for Non-Small Cell Lung Cancer

Ivonescimab, a novel treatment for first-line non-small cell lung cancer (NSCLC), is set to be a focal point at the upcoming ASCO 2026 annual meeting. Its plenary presentation status indicates that the results from the Harmoni-6 trial will undergo rigorous examination by experts in the field. This scrutiny is significant as it reflects the high expectations surrounding the drug's efficacy and safety profile in a competitive oncology landscape. The outcomes of this trial could have substantial implications for treatment protocols and patient outcomes in NSCLC, a leading cause of cancer-related mortality worldwide. As healthcare professionals prepare for the meeting, the anticipation builds regarding how ivonescimab will perform under critical evaluation and what this means for future therapeutic options in lung cancer management.

Fierce Pharma

Viridian Partners with WuXi Biologics for Eye Drug Manufacturing Ahead of FDA Decision

Viridian Therapeutics has entered into a manufacturing agreement with WuXi Biologics as it prepares for an upcoming FDA decision regarding its eye drug. This strategic partnership with the Chinese contract development and manufacturing organization (CDMO) is aimed at bolstering Viridian's capabilities to compete in the lucrative ophthalmic market, which is currently dominated by Amgen. The collaboration is expected to enhance production efficiency and scalability, positioning Viridian favorably as it seeks to launch its product. The outcome of the FDA review will be pivotal, not only for Viridian's market entry but also for its potential to disrupt existing treatment paradigms in eye care. As the company awaits the regulatory verdict, stakeholders are closely monitoring developments that could significantly impact the competitive landscape in this sector.

Fierce Pharma

Verge Genomics Rebrands as Verge Labs After Clinical Trial Setback in ALS Drug Development

Verge Genomics has rebranded itself as Verge Labs, a move that follows the failure of its early-stage clinical trial for VRG50635, an AI-discovered drug aimed at treating amyotrophic lateral sclerosis (ALS). The company, which laid off approximately 90% of its workforce, is shifting its focus to providing data-driven insights for drug developers to identify optimal targets for their experimental programs. CEO Alice Zhang emphasized that setbacks are common in drug development, whether through AI or traditional methods, and that valuable lessons can be learned from these experiences. The clinical trial for VRG50635, which targeted the enzyme PIKfyve involved in cellular waste disposal, did not yield the expected benefits for patients, as indicated by increased levels of neurofilament light chain, a marker associated with nerve cell damage. Despite this setback, Verge Labs plans to continue its work in neuroscience, partnering with developers to identify new drug targets, potential patients, and biomarkers. The company aims to monetize its datasets and insights, similar to strategies employed by other medtech firms like Tempus AI. Founded in 2015, Verge has raised over $100 million in venture capital and previously engaged in drug discovery collaborations with major pharmaceutical companies such as Eli Lilly and AstraZeneca. The restructuring includes hiring AI experts from notable organizations, indicating a commitment to enhancing its capabilities in drug discovery. As the landscape for AI-driven drug development evolves, Verge Labs seeks to carve out a niche by leveraging its data expertise to support the pharmaceutical industry in overcoming challenges in drug development.

BioPharma Dive · 4d ago

Kardigan, Cardiovascular Drugmaker, Announces Plans for Initial Public Offering

Kardigan, a California-based biotechnology startup focused on cardiovascular therapies, has announced its intention to go public. Founded in 2023 by former MyoKardia executives, the company aims to develop innovative treatments targeting the underlying causes of cardiovascular diseases that currently lack approved therapies. Kardigan has raised nearly $570 million to date, bolstered by a significant $254 million Series B funding round last fall, with investments from notable firms such as Perceptive Advisors and Sequoia Heritage. The company’s pipeline includes three in-licensed drugs in advanced stages of clinical testing. The lead candidate, danicamtiv, is undergoing a Phase 2b/3 trial for genetically driven dilated cardiomyopathy, a condition that impairs the heart's ability to pump blood. Another drug, tonlamarsen, is being evaluated in a Phase 2b trial for its potential to manage acute blood pressure spikes. Additionally, ataciguat is being tested for its efficacy in treating conditions related to calcium deposits that restrict blood flow. Kardigan's approach emphasizes the need for innovation in cardiovascular drug development, which has historically focused on symptom management rather than addressing root causes. The company aims to utilize real-time data collection and streamlined clinical trials to enhance the efficiency and success rates of its studies. However, the financial landscape remains challenging, with R&D costs rising significantly and net losses increasing, highlighting the potential need for capital from an IPO. The announcement comes at a time when biotech IPOs are experiencing a resurgence, with 11 already this year, indicating a growing investor interest in companies that can demonstrate promising clinical data. Kardigan's public offering could provide essential funding to support its ambitious research agenda and further its mission to transform cardiovascular care.

BioPharma Dive · 4d ago

Acadia Pharmaceuticals Expands 'More To Parkinson's' Campaign with Ryan Reynolds

Acadia Pharmaceuticals is revitalizing its 'More To Parkinson's' campaign, initially launched two years ago with actor Ryan Reynolds, to further raise awareness about Parkinson's disease. The campaign aims to highlight the multifaceted nature of the condition, emphasizing that there is more to the disease than just the well-known motor symptoms. By enlisting Reynolds once again, Acadia seeks to leverage his influence to reach a broader audience and foster a deeper understanding of the challenges faced by those living with Parkinson's. This initiative is particularly significant as it addresses the stigma and misconceptions surrounding Parkinson's disease, which affects approximately 1 million people in the United States alone. The campaign's expansion is expected to include new educational resources and outreach efforts to engage both patients and healthcare professionals. Acadia's commitment to this cause underscores the importance of ongoing dialogue and support for individuals impacted by this progressive neurological disorder. As the campaign progresses, Acadia aims to gather more data on public perceptions of Parkinson's and the effectiveness of their outreach strategies. The involvement of a high-profile figure like Reynolds not only raises awareness but also encourages discussions about the need for more research and better treatment options for those affected by the disease. The next steps for Acadia will likely involve partnerships with healthcare organizations and advocacy groups to maximize the campaign's impact.

Fierce Pharma

Calls to Expand COINS Act to Include Biotech Amid China Competition

As the U.S. faces increasing competition from China's burgeoning biotech industry, there is a rising demand among policymakers and industry experts for the Treasury Department to broaden the scope of the recently enacted COINS Act. This expansion would specifically target the biotechnology sector, imposing outbound investment restrictions on cross-border drug transactions. The urgency of this proposal reflects concerns over national security and the need to safeguard American innovation in the face of China's rapid advancements in biotechnology. If implemented, these new rules could significantly impact U.S. biotech firms engaged in international collaborations and investments, potentially reshaping the landscape of global drug development. Stakeholders are closely monitoring the situation as discussions continue, with implications for both domestic and international biotech operations.

Fierce Pharma

Eli Lilly's VERVE-102 Shows Promise in Lowering Cholesterol, Paving Way for Phase 2 Trials

Eli Lilly has reported promising early results from its experimental cholesterol-lowering drug, VERVE-102, which utilizes base editing technology to target low-density lipoprotein (LDL) levels in patients with genetically elevated cholesterol and early-onset heart disease. In a recent trial, a single infusion of VERVE-102 led to a significant reduction in LDL levels by as much as 62%, with effects sustained for up to 18 months. This reduction is comparable to that achieved by Amgen's Repatha, although the two drugs have not been directly compared in clinical trials. The drug was acquired by Eli Lilly through a $1 billion purchase of Verve Therapeutics, a startup focused on genetic solutions for cardiovascular diseases. VERVE-102 represents a novel approach by editing the PCSK9 gene, which plays a crucial role in regulating LDL metabolism in the liver. This innovative strategy aims to address the limitations of existing treatments, such as statins and PCSK9 inhibitors, which many patients find intolerable or ineffective. Cardiovascular disease remains a leading cause of mortality globally, highlighting the urgent need for new therapeutic options. The data from the trial, presented at the European Atherosclerosis Society Congress and published in the New England Journal of Medicine, involved 35 participants who received varying doses of the drug. Results indicated a significant drop in PCSK9 levels (between 55% and 88%) alongside the reduction in LDL levels. Importantly, there were no serious treatment-related adverse events reported, with side effects primarily consisting of infusion reactions and fatigue. Looking ahead, Eli Lilly plans to initiate a Phase 2 study by the end of 2026, which could further validate the efficacy and safety of VERVE-102. If successful, this drug could solidify Lilly's leadership in metabolic disease treatments, complementing its existing portfolio of obesity and diabetes medications.

BioPharma Dive · 5d ago

Eli Lilly Expands Infectious Disease Portfolio with $4 Billion in Vaccine Developer Acquisitions

Eli Lilly has announced its intention to enhance its infectious disease portfolio through the acquisition of three vaccine developers: Vaccine Co., Curevo, and LimmaTech Biologics, for a total of nearly $4 billion. This strategic move, revealed on May 26, 2026, marks a significant expansion for Lilly, which has been actively acquiring biotech firms this year, having already purchased ten companies in various therapeutic areas including oncology and immunology. The financial details of the acquisitions remain undisclosed, but estimates suggest that the deals could be valued at approximately $1.55 billion for Vaccine Co., $1.5 billion for Curevo, and up to $780 million for LimmaTech, contingent on milestone achievements. This initiative reflects Lilly's commitment to addressing infectious diseases, which are recognized as a major source of global morbidity. The company aims to prevent diseases at their source rather than merely treating their consequences, as articulated by Daniel Skovronsky, Lilly’s chief scientific and product officer. Curevo's lead asset is an experimental shingles vaccine that utilizes a next-generation synthetic adjuvant, showing promise in Phase 2 trials by generating a comparable immune response to existing vaccines while reducing side effects. LimmaTech is developing vaccines targeting bacterial infections, particularly Staphylococcus aureus, which is a significant concern due to rising antimicrobial resistance. Vaccine Co. is working on a preclinical vaccine for Epstein-Barr Virus, associated with multiple sclerosis and various cancers, and has received funding from the Advanced Research Projects Agency for Health (ARPA-H). This acquisition strategy not only diversifies Lilly's portfolio but also positions the company to play a pivotal role in combating infectious diseases, an area where it has historical involvement, including its past contributions to the polio vaccine and recent efforts in COVID-19 antibody treatments. As Lilly continues to invest in this sector, the healthcare community will be watching closely for developments in these promising vaccine candidates.

BioPharma Dive · 5d ago

EMA Updates Recommendations for 2026/2027 Seasonal Influenza Vaccine Composition

The European Medicines Agency (EMA) has released updated recommendations for the composition of seasonal influenza vaccines for the 2026/2027 season, following observations from the World Health Organization (WHO). These recommendations are crucial for vaccine manufacturers as they prepare to combat seasonal influenza, which continues to pose a public health challenge. The EMA's guidance includes specific strains to be incorporated into both egg-derived and live-attenuated vaccines, as well as cell-based vaccines. For the upcoming flu season, manufacturers of egg-based and live-attenuated vaccines are advised to include an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Darwin/1454/2025 (H3N2)-like virus, and a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus. In contrast, cell-based vaccines should feature an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Darwin/1415/2025 (H3N2)-like virus, and a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus. Notably, the B/Yamagata strain will not be included in the recommendations, as it has not been detected since March 2020, reflecting a shift in the epidemiological landscape of influenza viruses. The EMA's recommendations were endorsed by the Committee for Medicinal Products for Human Use (CHMP) during its March 2026 plenary meeting. This decision underscores the importance of adapting vaccine formulations to ensure continued effectiveness against evolving influenza strains. Manufacturers are encouraged to submit applications for changes to the composition of centrally authorized seasonal influenza vaccines by June 15, 2026, to align with these updated guidelines. The proactive approach taken by the EMA and WHO aims to enhance public health preparedness for the upcoming flu season.

EMA News · 5d ago

Targeted Protein Degraders: A New Approach to Targeting KRAS in Cancer Treatment

Recent insights from Astellas' Head of Oncology Development highlight the potential of targeted protein degraders in eliminating KRAS, a key driver in various cancers. KRAS mutations are prevalent in approximately 25% of all cancers, making it a significant target for therapeutic intervention. The development of these degraders represents a shift in cancer treatment paradigms, moving beyond traditional inhibitors to a strategy that promotes the degradation of the KRAS protein itself. This innovative approach could lead to more effective treatments for patients with KRAS-driven tumors, which have historically been challenging to treat. By targeting the protein for degradation rather than merely inhibiting its activity, these degraders may offer a more comprehensive solution, potentially improving patient outcomes and survival rates. As the research progresses, the implications for clinical practice are substantial. If successful, targeted protein degraders could not only redefine treatment options for patients with KRAS mutations but also pave the way for similar strategies against other hard-to-treat oncogenic proteins. The oncology community is closely monitoring these developments, as they could significantly alter the landscape of cancer therapy in the near future.

Fierce Pharma

Merck-Kelun ADC Achieves Triple Success in Phase 3 Trials Amid Licensing Insights in China

Merck & Co. and Kelun-Biotech have reported significant success with their antibody-drug conjugate (ADC), sac-TMT, achieving positive results in three separate phase 3 clinical trials. This milestone not only highlights the potential of sac-TMT in treating specific cancers but also underscores the importance of robust clinical development strategies in the competitive biopharmaceutical landscape. The successful trials are expected to accelerate the drug's path to market, potentially benefiting patients with limited treatment options. In addition to the clinical achievements, experts emphasize the growing importance of local expertise and thorough due diligence in navigating the complex landscape of licensing deals in China. The integration of artificial intelligence (AI) in these processes is becoming increasingly vital, as it aids companies in making informed decisions and optimizing their strategies for market entry. In a separate legal development, a federal jury has made a landmark ruling, holding a drug manufacturer accountable in a pay-for-delay case for the first time. This ruling could have significant implications for the pharmaceutical industry, potentially altering how companies approach patent settlements and competition in the market. The outcome may encourage further scrutiny of similar practices, impacting both drug pricing and availability. As these developments unfold, stakeholders in the healthcare sector will be closely monitoring the implications for drug development, market access strategies, and regulatory frameworks, particularly in emerging markets like China.

Fierce Pharma

AbbVie and GSK Climb UK Patient Reputation Rankings

AbbVie and GSK have made significant strides in the reputation rankings among pharmaceutical companies in the UK, as assessed by patient groups. This improvement reflects their commitment to patient engagement and satisfaction, which is increasingly important in the healthcare landscape. The rise in reputation is likely to influence their market performance and relationships with healthcare providers and patients alike. As these companies continue to enhance their reputations, they may see a positive impact on their turnover and overall business success. The ongoing competition in the pharmaceutical sector underscores the importance of patient perception in shaping company strategies and outcomes.

Fierce Pharma

AbbVie and Novartis Announce Layoffs at Opposite Coasts Amid Industry Adjustments

AbbVie and Novartis are set to implement significant layoffs this summer, affecting their operations on opposite coasts of the United States. AbbVie plans to reduce its workforce by 85 positions at its Allergan Aesthetics headquarters located in California. This move is part of a broader strategy to streamline operations and respond to market demands in the aesthetics sector. Meanwhile, Novartis is also making cuts at its U.S. headquarters in New Jersey, although specific numbers have not been disclosed. These layoffs reflect ongoing challenges within the pharmaceutical industry, including shifts in consumer demand and the need for companies to adapt to changing market conditions. The impact of these layoffs will be felt by employees and may also influence the companies' operational capabilities moving forward. As both companies navigate these changes, stakeholders will be watching closely for further developments and potential implications for their respective markets.

Fierce Pharma

Europe's CHMP Approves AstraZeneca's Etcamah for Breast Cancer Following FDA Rejection

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for AstraZeneca's Etcamah, a novel treatment for breast cancer. This decision comes less than a month after an FDA advisory committee recommended against the drug's approval in the United States, highlighting the differing regulatory perspectives between Europe and the U.S. The approval is significant as it provides a new therapeutic option for patients battling breast cancer, a condition that affects millions globally. Additionally, the CHMP has also approved Novo Nordisk's Wegovy, a medication aimed at weight management, indicating a broader trend of advancing treatment options in Europe. The next steps for AstraZeneca will involve final approval from the European Commission, which is expected to follow the CHMP's recommendation, potentially allowing Etcamah to reach patients in Europe soon.

Fierce Pharma

Key Clinical Trial Updates Ahead of ASCO26 Highlight Promising Cancer Therapies

As the American Society of Clinical Oncology (ASCO) prepares for its annual meeting in Chicago from May 29 to June 2, several significant clinical trial updates have emerged. These updates, released in the form of abstracts, provide insights into the latest advancements in cancer therapies, although they do not include late-breaking abstracts that will be revealed during the conference. Notably, Merck & Co.'s sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate targeting the TROP2 protein, has shown promising results in a Phase 3 trial for non-small cell lung cancer (NSCLC). When combined with Keytruda, sac-TMT reduced the risk of disease progression by 65% and achieved a response rate of over 70%, indicating its potential as a significant treatment option. In addition, Akeso and Summit Therapeutics are set to present data on their cancer immunotherapy ivonescimab, which is anticipated to be a key player in the PD-1/VEGF inhibitor space. Other companies, including BioNTech and Bristol Myers Squibb, are also showcasing their developments in this area, with promising results from their drug pumitamig. Meanwhile, Pfizer's SSGJ-707 has demonstrated a 68% response rate in newly diagnosed NSCLC patients, further contributing to the competitive landscape of cancer treatments. Eli Lilly's investment in Kelonia Therapeutics is also highlighted, with their in vivo CAR-T therapy KLN-101 showing potential advantages over existing therapies. As these findings unfold at ASCO26, they are expected to shape the future of cancer treatment and influence the strategies of various pharmaceutical companies in the oncology market.

BioPharma Dive · May 22

EMA Recommends Jascayd for Treating Pulmonary Fibrosis in Adults

The European Medicines Agency (EMA) has recommended granting marketing authorization for Jascayd (nerandomilast) in the EU, aimed at treating adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). These conditions are characterized by progressive and irreversible lung scarring, leading to severe symptoms such as difficulty breathing, which can result in hospitalization and a high mortality rate within a few years of diagnosis. The introduction of Jascayd is significant as it offers a new mechanism of action compared to existing treatments, targeting the PDE4B enzyme involved in fibrosis and inflammation in the lungs. Clinical data supporting the EMA's recommendation comes from two pivotal studies involving 2,355 patients. The primary endpoint was the decline in lung function over one year, measured by forced vital capacity (FVC). Results indicated that patients receiving Jascayd experienced a significantly slower decline in FVC compared to those on placebo. Specifically, in the IPF study, the average decrease in FVC was 115 ml for those on the higher dose of Jascayd, compared to 183 ml for placebo. Similarly, in the PPF study, the figures were 99 ml versus 166 ml, respectively. Additionally, Jascayd treatment appeared to reduce mortality rates among participants. Jascayd is administered orally, with a recommended dosage of 18 mg twice daily, adjustable to 9 mg for patients experiencing side effects such as diarrhea or weight loss. However, caution is advised for patients also taking pirfenidone, as it can affect nerandomilast levels. The most common side effects reported include diarrhea and weight loss. The EMA's recommendation is a crucial step towards making Jascayd available to patients, with the next phase involving a decision from the European Commission regarding its marketing authorization. Following this, pricing and reimbursement discussions will occur at the national level across EU member states, considering the drug's role within their healthcare systems.

EMA News · May 22

Ipsen Highlights Challenges in Transitioning Teens to Adult Healthcare

A recent survey commissioned by Ipsen has revealed significant challenges faced by adolescents transitioning from pediatric to adult healthcare services. The findings indicate that many young patients encounter difficulties during this critical shift, which can impact their ongoing health management and overall well-being. Ipsen emphasizes the need for enhanced resources and support systems to facilitate smoother transitions for these individuals, ensuring they receive appropriate care as they age out of pediatric services. This issue is particularly relevant as it affects a substantial population of teenagers and young adults who require continuous medical attention. The call for action from Ipsen aims to address these gaps in care and improve health outcomes for this vulnerable demographic.

Fierce Pharma

Big Pharma Sees Growth in Q1 2023, Led by Lilly, AbbVie, J&J, and AZ

In the first quarter of 2023, the biopharmaceutical sector experienced a notable increase in sales, with eight of the top 25 companies reporting double-digit year-over-year growth. This marks an improvement from 2022, where only six companies achieved similar growth across all four quarters. The performance of these leading firms, including Lilly, AbbVie, Johnson & Johnson, and AstraZeneca, highlights a positive trend in the industry, suggesting a recovery and potential for sustained growth in the coming months. This uptick is significant as it reflects the ongoing demand for innovative therapies and the resilience of the pharmaceutical market amidst economic challenges. As these companies continue to expand their portfolios and address unmet medical needs, stakeholders will be closely monitoring their strategies and market performance in the upcoming quarters.

Fierce Pharma

Gilead Commits 400,000 Doses of AmBisome to Combat Visceral Leishmaniasis in WHO Partnership

Gilead Sciences has announced a significant commitment to public health by pledging 400,000 doses of its antifungal medication AmBisome over a five-year period. This initiative is part of a collaborative effort with the World Health Organization (WHO) aimed at addressing visceral leishmaniasis, a parasitic disease that poses a serious health threat in several regions. The countries targeted by this partnership account for approximately 74% of the global burden of visceral leishmaniasis, highlighting the critical need for effective treatment options in these areas. Visceral leishmaniasis, also known as kala-azar, is a severe form of leishmaniasis that can be fatal if left untreated. The disease is endemic in parts of Africa, Asia, and South America, affecting vulnerable populations, particularly those with weakened immune systems. Gilead's provision of AmBisome is expected to enhance treatment accessibility and improve health outcomes for affected individuals. This collaboration underscores the importance of public-private partnerships in addressing global health challenges. By supplying AmBisome, Gilead aims to support WHO's efforts in controlling and eliminating visceral leishmaniasis, which remains a neglected tropical disease. The initiative is a step forward in the fight against this debilitating condition, and it sets a precedent for future collaborations between pharmaceutical companies and international health organizations. As the program unfolds, stakeholders will be monitoring the impact of these doses on treatment rates and disease prevalence in the targeted regions. The commitment from Gilead not only reflects corporate responsibility but also emphasizes the urgent need for sustained efforts to combat neglected diseases worldwide.

Fierce Pharma

New ADC Combination Shows 65% Improvement Over Keytruda in First-Line Lung Cancer Treatment

A recent abstract presented ahead of the ASCO 2026 annual meeting highlights significant advancements in the treatment of treatment-naïve, PD-L1-positive non-small cell lung cancer (NSCLC). The study reveals that the combination of a TROP2-directed antibody-drug conjugate (ADC) developed by Merck and Kelun, when used alongside Keytruda, reduces the risk of disease progression or death by 65% compared to Keytruda alone. This finding is particularly important as it offers a promising new option for patients who have not yet received treatment, potentially improving outcomes in a population that often faces poor prognoses. The implications of this study are profound, as NSCLC remains one of the leading causes of cancer-related deaths worldwide. The enhanced efficacy of this combination therapy could lead to changes in clinical practice guidelines and treatment protocols, providing oncologists with a more effective strategy to combat this aggressive disease. The data underscores the importance of innovative therapies in the ongoing battle against lung cancer, which continues to challenge healthcare providers. As the medical community awaits further details from the ASCO meeting, the focus will likely shift to the next steps in clinical development and potential regulatory approvals for this combination therapy. If successful, it could pave the way for broader applications of ADCs in oncology, marking a significant milestone in lung cancer treatment.

Fierce Pharma

Bristol Myers Squibb Expands Alzheimer's Research Beyond Amyloid Targeting

Bristol Myers Squibb (BMS) is venturing into the complex field of neuroscience, particularly focusing on Alzheimer's disease, as it seeks to diversify its drug pipeline. The company, known for its significant acquisitions and successful products like Opdivo, is now exploring innovative treatment avenues beyond the traditional amyloid hypothesis. With a recent $14 billion acquisition that introduced Cobenfy, a novel schizophrenia medication, BMS aims to leverage this asset in treating conditions like bipolar mania and Alzheimer's-related psychosis. Clinical trials for these applications are underway, with results expected soon, which could shape the future of their psychiatry franchise. BMS executives emphasize the importance of a balanced approach in their research, targeting both symptomatic relief and disease modification in Alzheimer's treatment. While amyloid remains a validated target, the company is also investigating tau proteins and neuroinflammation as potential therapeutic avenues. The leadership believes that early intervention in Alzheimer's can lead to better patient outcomes, supported by advanced biomarker tools that enhance trial efficacy. The company's commitment to exploring diverse mechanisms in Alzheimer's treatment reflects a broader trend in the pharmaceutical industry, where reliance solely on amyloid-targeting therapies is being reconsidered. As BMS continues to develop its pipeline, the outcomes of their ongoing studies could significantly impact the landscape of Alzheimer's treatment and the company's future in neuroscience.

BioPharma Dive · May 21

EMA Office Closure on Whit Monday: Key Information for Healthcare Professionals

The European Medicines Agency (EMA) will be closed on May 25 to observe Whit Monday, a public holiday in several European countries. The office will resume operations at 08:30 on May 26. This closure is significant for healthcare professionals and organizations relying on EMA's services, as it may affect the processing of urgent inquiries or submissions during this period. However, the EMA has established a product emergency hotline that remains operational outside of regular working hours and on public holidays. Healthcare providers and stakeholders can reach this hotline at +31 (0)88 781 7600 for urgent matters related to centrally authorized products. It is crucial to use this number only in cases of potentially serious issues, ensuring that the hotline remains available for genuine emergencies.

EMA News · May 21

CG Life Appoints Collette Douaihy as Chief Creative Officer to Enhance Biopharma Services

CG Life has announced the appointment of Collette 'Coco' Douaihy as its new Chief Creative Officer. Douaihy, who previously held leadership roles at Dentsu International, Evoke, and Digitas Health, will spearhead the agency's creative initiatives aimed at biopharmaceutical companies. This strategic hire is part of CG Life's ongoing efforts to strengthen its executive team and enhance its service offerings in the biopharma sector. Douaihy's extensive experience in health marketing is expected to bring innovative strategies and creative solutions to CG Life's clients, ultimately aiming to improve engagement and communication in the healthcare landscape. As the biopharma industry continues to evolve, CG Life's focus on creative leadership positions it to better meet the needs of its clients and adapt to changing market dynamics.

Fierce Pharma

Tarsus Pharmaceuticals Enlists John Cena for Demodex Blepharitis Awareness Campaign

Tarsus Pharmaceuticals has launched a new campaign to raise awareness about Demodex blepharitis, a condition affecting the eyelids caused by microscopic mites. This initiative comes after three years of efforts to destigmatize the largely unknown disease, which can lead to discomfort and irritation for those affected. By partnering with celebrity John Cena, Tarsus aims to reach a broader audience and educate the public on the symptoms and treatment options available for this condition. The campaign is significant as it highlights the importance of addressing lesser-known health issues and encourages individuals experiencing symptoms to seek medical advice. Moving forward, Tarsus plans to continue its outreach efforts to further inform healthcare professionals and patients about Demodex blepharitis and its management.

Fierce Pharma

Parabilis Medicines Files for IPO After Securing $800M in Funding to Target 'Undruggable' Cancer Proteins

Parabilis Medicines, a biotech startup focused on developing innovative therapies for challenging cancer targets, has filed for an initial public offering (IPO) following a significant $305 million Series F funding round earlier this year. The company, which has raised over $800 million in total private funding since its inception in 2015, aims to leverage its proprietary 'Helicons' technology to target proteins that traditional drugs cannot reach. This IPO comes at a time when biotech companies are experiencing a resurgence in public offerings, with an average of $286 million raised per company in 2026. The lead candidate, FOG-001, is currently being tested in early-stage trials for desmoid tumors, a rare type of non-cancerous growth. Preliminary data indicates that FOG-001 can effectively shrink or stabilize tumors in most patients. The FDA has granted the drug orphan drug and fast-track designations, which could expedite its development and review process. Parabilis is also preparing to initiate a Phase 3 trial for this indication, with plans to explore its application in more prevalent cancer types. In addition to desmoid tumors, Parabilis is investigating FOG-001's efficacy in treating inherited conditions that lead to polyp growth in the digestive tract and rare brain tumors. The drug targets the interaction between β-catenin and TCF transcription factors, which are implicated in various cancers. The company is also exploring treatments for prostate cancer and has conducted studies in liver and colorectal tumors. With Mathai Mammen, a former Johnson & Johnson executive, at the helm, Parabilis is poised to make significant strides in oncology. The company’s innovative approach and substantial funding position it well for future growth and development in the competitive biotech landscape.

BioPharma Dive · May 20

FDA Targets Retailers Selling Unauthorized Tobacco Products Mimicking Everyday Items

The U.S. Food and Drug Administration (FDA) has issued warning letters to eight retailers for selling unauthorized tobacco products that resemble everyday items such as candy, breath strips, and cough drops. These products, including nicotine pouches and dissolvable tobacco, pose significant risks, particularly to children, who may accidentally ingest them or be attracted to their deceptive packaging. The FDA's acting director of the Center for Tobacco Products, Bret Koplow, emphasized that tobacco products should not mimic candy, highlighting the agency's commitment to preventing such marketing tactics that target minors. The warning letters are part of a broader enforcement strategy aimed at removing unauthorized tobacco products from the market, especially those appealing to younger audiences. Retailers are required to address the violations outlined in the letters and take corrective actions to comply with the Federal Food, Drug, and Cosmetic Act. Failure to do so could lead to further FDA actions, including injunctions or civil penalties. To date, the FDA has issued over 800 warning letters to manufacturers and more than 1,000 to retailers regarding unauthorized tobacco products. The agency has also released guidance on enforcement priorities for electronic nicotine delivery systems (ENDS) and nicotine pouch products lacking premarket authorization. This initiative underscores the FDA's ongoing efforts to protect public health and ensure that consumers are not exposed to potentially harmful products that have not undergone rigorous scientific evaluation.

FDA News · May 20

EU Reports Initial Progress on 2030 Clinical Trial Targets

The European Commission, along with the Heads of Medicines Agencies and the European Medicines Agency, has released its inaugural report assessing progress towards the EU's clinical trial targets set for 2030. These targets, established in 2025, aim to enhance the EU's status as a premier location for clinical research and to facilitate timely access for patients to innovative therapies. The report, which covers activities from January 1 to March 31, 2026, indicates a promising start, with 19 additional multinational clinical trials authorized, moving closer to the goal of 500 extra trials by 2030. Recruitment timelines have also shown improvement, with 40.5% of clinical trials currently enrolling participants within 200 days of application submission, compared to the target of 66% by 2030. Preliminary data collected post-March 2026 suggests ongoing positive trends across key performance indicators, indicating that the EU is on track to meet its ambitious goals. The next quarterly report is expected to provide further insights into these developments. This report is part of the Accelerating Clinical Trials in the EU (ACT EU) initiative, which aligns with the proposed EU Biotech Act. A significant aspect of this initiative is the acceleration of clinical trial authorization processes across member states. Additionally, the FAST-EU pilot program, led by HMA, offers sponsors a chance to test expedited evaluation timelines for multinational trials within the current legal framework. The publication of these key performance indicators is a crucial step towards enhancing transparency and accountability in the EU clinical trials landscape, addressing stakeholder demands for clearer, evidence-based insights into system performance. Future progress will be reviewed annually by ACT EU governance, ensuring that the targets remain both ambitious and achievable, ultimately fostering a more attractive environment for high-quality clinical research in the EU.

EMA News · May 20

Eli Lilly Acquires Engage Biologics to Enhance Non-Viral Genetic Medicine Development

Eli Lilly has announced the acquisition of Engage Biologics, a biotechnology firm specializing in non-viral genetic medicine delivery, in a deal valued at up to $202 million. This strategic move is part of Lilly's ongoing commitment to advancing genetic therapies, which have shown promise in treating severe conditions but have faced challenges due to reliance on viral vectors. Engage's proprietary 'Tethosome' platform utilizes lipid nanoparticles for DNA delivery, aiming to improve safety, tolerability, and reusability compared to traditional methods. The acquisition is significant as it addresses longstanding limitations in the field of gene therapy, particularly the safety risks and manufacturing complexities associated with adeno-associated viruses (AAVs). Engage's technology combines DNA payloads with lipid nanoparticles and messenger RNA sequences to enhance cellular uptake, potentially accelerating the development of new therapies. This innovative approach aligns with the growing trend among biotech startups to explore alternative delivery methods. Lilly's acquisition of Engage follows its earlier purchase of Orna Therapeutics, further solidifying its position in the genetic medicine landscape. The company, known for its diabetes and weight-loss medications, is expanding its pipeline to include gene editing and therapy solutions for various conditions, including hearing loss and high cholesterol. Engage, founded in 2021 and based in San Carlos, California, has garnered support from notable investors and organizations, including Y Combinator and the Gates Foundation, indicating strong backing for its innovative approach. As Lilly integrates Engage's technology, the pharmaceutical giant aims to enhance its capabilities in genetic medicine, potentially leading to breakthroughs in treatment options for patients with genetic disorders. The next steps will involve leveraging Engage's platform to develop and commercialize new therapies, with the potential for significant advancements in the field of genetic medicine.

BioPharma Dive · May 20

White House Expands TrumpRx Portal with 600 New Generic Medications

The White House has announced the addition of 600 generic medications to the TrumpRx purchasing portal, aiming to enhance access to affordable drugs for consumers. This update comes amid ongoing discussions regarding the portal's effectiveness in reducing medication costs. While the expansion is a step towards improving the platform, concerns about the actual affordability and accessibility of these medications persist. Healthcare professionals and patients alike are encouraged to monitor the developments closely, as the impact of these changes on drug pricing and availability remains to be fully assessed. The next steps will involve evaluating the portal's performance and addressing any remaining gaps in its offerings.

Fierce Pharma

Mentari Therapeutics to Go Public via Reverse Merger with InMed Pharmaceuticals

Mentari Therapeutics, a private company focused on migraine prevention, is set to enter the public markets through a reverse merger with InMed Pharmaceuticals. This strategic move, announced on Tuesday, has received board approval from both companies and is expected to finalize later this year. The merger will result in a combined entity valued at approximately $421 million, with InMed shareholders retaining about 1.5% ownership. A concurrent private placement led by Fairmount is projected to generate around $290 million, providing substantial funding for the new company, which will operate under the Mentari name until at least 2028. The merger is significant as it positions Mentari to advance its two lead programs, MT-001 and MT-002, which target the PACAP protein implicated in migraine pathophysiology. Current statistics indicate that nearly half of migraine patients do not achieve a 50% reduction in monthly migraine days with existing treatments, highlighting the urgent need for more effective therapies. Mentari's MT-001 is expected to yield Phase 2 proof-of-concept data by 2028, while MT-002, a bispecific antibody targeting both PACAP and CGRP, aims to provide additional options for patients. The deal is seen as a promising opportunity for InMed shareholders to engage in a potentially transformative drug pipeline. InMed's CEO, Eric Adams, emphasized the therapeutic and commercial potential of Mentari's programs, which could reshape the migraine treatment landscape. The new Mentari will trade on the Nasdaq under a new ticker symbol, with leadership from the existing Mentari board and key figures from Fairmount and Paragon Therapeutics. This merger not only reflects the growing interest in innovative migraine therapies but also underscores the competitive landscape, as other companies like Lundbeck and Slate Medicines are also targeting PACAP and CGRP pathways for migraine prevention.

BioPharma Dive · May 19